Tenaya Therapeutics filings document a clinical-stage biotechnology issuer focused on genetic and small-molecule approaches to heart disease. Recent 8-K reports furnish operating results and corporate updates tied to TN-201, TN-401 and TN-301, including clinical and regulatory disclosures for cardiomyopathy programs and research updates for cardiovascular target validation.
The company’s SEC record also includes definitive proxy materials for annual-meeting governance and shareholder voting matters, material-agreement disclosure for its cardiovascular target research collaboration, capital-structure information and Nasdaq continued-listing compliance disclosures. These filings frame Tenaya’s public reporting around pipeline development, financing capacity, governance and common stock status.
Tenaya Therapeutics asks stockholders to approve an amendment authorizing the board, at its discretion, to reverse split issued and outstanding or treasury common shares at a ratio from 1-for-10 to 1-for-25; the board would choose the exact ratio. The board recommends a vote “FOR.” If approved, it may implement or abandon the split before the one-year anniversary of the special meeting. Authorized common and preferred shares would remain at 1,000,000,000 and 200,000,000, respectively, and fractional shares would be settled in cash.
The proposal follows a Nasdaq notice that Tenaya’s bid price had been below $1.00 for 30 consecutive business days. A transfer to the Nasdaq Capital Market gave the company an additional 180-day compliance period through January 25, 2027; compliance requires a closing bid of at least $1.00 for 10 consecutive business days by then. The closing sale price was $0.38 per share on October 19, 2026, when 227,928,240 common shares were outstanding. Tenaya says it cannot assure the split would raise the share price or maintain Nasdaq listing, and notes that fewer shares could reduce liquidity and increase costs for odd-lot trades.
Tenaya Therapeutics, Inc. (TNYA) is asking stockholders to authorize a reverse stock split of its common stock at a ratio from 1-for-10 to 1-for-25, subject to the board’s discretion to choose the final ratio and whether to implement it. The board says the proposal is intended to help maintain the Nasdaq Capital Market listing after Nasdaq notified Tenaya on January 28, 2026, that its bid price had been below $1.00 per share for 30 consecutive business days. Following a transfer to the Nasdaq Capital Market, Tenaya has until January 25, 2027, to regain compliance by having a closing bid price of at least $1.00 for 10 consecutive business days.
If approved and implemented, the split would reduce outstanding shares proportionately, with fractional interests paid in cash, while authorized shares would remain at 1,000,000,000 common and 200,000,000 preferred. Tenaya says total stockholders’ equity would remain unchanged. The split is not assured to raise the share price or preserve the listing, and the board may abandon the proposal before the one-year anniversary of the December 9, 2026, special meeting. The meeting will be virtual.
Tenaya Therapeutics, Inc. (symbol: TNYA) is the issuer of record for a Form 4 filing submitted to the SEC. Ali Faraz reported acquisition or exercise transactions in this Form 4 filing.
Tenaya Therapeutics, Inc. (TNYA) reported that Chief Executive Officer and director Ali Faraz received equity awards on September 10, 2026. He was granted 732,500 stock options exercisable at $0.6488 per share and 122,000 restricted stock units, all under the Amended and Restated 2021 Equity Incentive Plan, with multi-year vesting schedules.
Tenaya Therapeutics, Inc. (TNYA) reported that Chief Medical Officer Tingley Whittemore received equity awards on September 10, 2026. These include a stock option for 293,000 shares of common stock at an exercise price of $0.6488 per share, vesting monthly over four years, and 49,000 restricted stock units vesting in semiannual installments starting February 15, 2027. Following the RSU grant, Whittemore directly holds 263,073 shares of common stock, including 142,076 shares subject to RSU vesting. No Rule 10b5-1 trading plan is reported.
Tenaya Therapeutics, Inc. (TNYA) is reported to have a significant shareholder group led by Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander under a Schedule 13G. Integrated Core Strategies (US) LLC reports beneficial ownership of 11,579,445 shares of Tenaya common stock. Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial ownership of 11,581,565 shares, representing 5.2% of Tenaya’s outstanding common stock. For each reporting person, sole voting and dispositive power is 0, while shared voting and shared dispositive power correspond to the reported share amounts. The filing also includes a Joint Filing Agreement among the reporting persons.
Tenaya Therapeutics, Inc. director and Chief Executive Officer Ali Faraz reported selling an aggregate 22,232 shares of common stock on 2026-08-17 in four open-market transactions at weighted average prices of about $0.71 per share. Footnotes state each sale covered tax withholding obligations arising from the vesting of restricted stock units granted on February 15, 2023, February 23, 2024, February 6, 2025, and February 3, 2026, respectively. Additional disclosure notes future issuance of 305,956, 295,331, 281,894, and 262,069 shares upon vesting of these restricted stock units.
Tenaya Therapeutics, Inc. Chief Medical Officer Whittemore Tingley reported open-market sales of 7,424 shares of common stock on August 17, 2026 at a weighted average price of $0.7098 per share, with individual trade prices ranging from $0.6820 to $0.7253. Footnotes state these sales were made to cover tax withholding obligations arising from the vesting of restricted stock units granted in 2023, 2024, 2025, and 2026, rather than as discretionary portfolio trades. Related footnotes also note substantial unvested restricted stock units that will be delivered in future, including 108,544, 104,169, 99,169, and 93,076 shares tied to different award dates, plus 6,000 shares acquired under the 2021 Employee Stock Purchase Plan.
Tenaya Therapeutics reported Q2 2026 collaboration revenue of $1,110 (in thousands), its first reported revenue, primarily from a new multi-target research agreement with Alnylam and related collaborations. Total operating expenses rose 88% to $45,198 (in thousands), driven by a $21,821 (in thousands) impairment on its decommissioned Genetic Medicine Manufacturing Center and a $1,368 (in thousands) loss on lease termination, partly offset by lower research and development and general and administrative spending.
The company recorded a Q2 net loss of $43,393 (in thousands) and a six-month net loss of $62,665 (in thousands), compared with $23,283 (in thousands) and $50,147 (in thousands) in 2025. Net cash used in operating activities was $22,786 (in thousands) for the first half, and cash and cash equivalents were $78,085 (in thousands) as of June 30, 2026. Management expects existing cash to fund operations for at least 12 months after filing. Tenaya continues to advance three lead programs: TN-201 and TN-401, AAV9-based gene therapies for genetically defined cardiomyopathies with interim data showing structural, arrhythmia and symptom improvements, and TN-301, an oral HDAC6 inhibitor being positioned for proof-of-activity trials in heart failure with preserved ejection fraction and Duchenne muscular dystrophy.